Bristol Myers’ (BMY) Krazati Gets FDA Nod for Colorectal Cancer

Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.